Ixazomib (Ninlaro) is an oral proteasome inhibitor approved in late 2015. It is now being used in a wide variety of treatment combinations and is also being evaluated as maintenance therapy.
For patients who have received prior treatment and achieved some sort of major response (complete response, very good partial response or partial response), investigators are comparing ixazomib maintenance vs. no maintenance. The study will help investigators understand the impact of ixazomib as maintenance therapy and how it impacts progression free survival compared to no maintenance therapy.
The study is open at 6 myeloma academic centers and is only for patients who have NOT undergone a stem cell transplant. To learn more, click the button below:Ixaxomib Maintenance Trial